The Project

In December of 2012, RLB Holdings became a cornerstone investor in Kineta Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of novel drug candidates derived from leading-edge scientific research.

The Benefit

Through this partnership, RLB provides funding for Kineta's research and development of their life-changing classes of new drugs which will improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain.  

Latest NewsVisit Website